Scherpbier H J, Prakken A B, de Graeff-Meeder E R, van den Berg H
Academisch Medisch Centrum, afd. Kindergeneeskunde, Amsterdam.
Ned Tijdschr Geneeskd. 1993 Aug 7;137(32):1610-3.
12 HIV-infected children were treated with a high dose of zidovudine (800/mg/m2/day) during a mean follow up period of 18 months. After starting treatment with zidovudine there was a subjective improvement and an increase in body weight, and a significant decline in serum HIV-antigenemia (p < 0.01) and serum IgG levels (p < 0.05). Zidovudine was generally well tolerated but there was serious hematological toxicity. In 9 patients (75%) dose reduction was necessary because of severe anemia (3 patients) or leucopenia (6 patients). Because of the high incidence of these side effects the starting dose of zidovudine was reduced to 600 mg/m2/day. These results confirm that zidovudine can safely be used to treat HIV-infected children. The main limitation is serious hematological toxicity which appears to be dose-related.
12名感染艾滋病毒的儿童在平均18个月的随访期内接受了高剂量齐多夫定（800毫克/平方米/天）治疗。开始使用齐多夫定治疗后，患儿主观症状改善，体重增加，血清艾滋病毒抗原血症（p < 0.01）和血清IgG水平显著下降（p < 0.05）。齐多夫定总体耐受性良好，但存在严重的血液学毒性。9名患者（75%）因严重贫血（3例）或白细胞减少（6例）需要减少剂量。由于这些副作用的高发生率，齐多夫定的起始剂量降至600毫克/平方米/天。这些结果证实，齐多夫定可安全用于治疗感染艾滋病毒的儿童。主要局限性是严重的血液学毒性，这似乎与剂量相关。
